Skip to main content

Life Threatening Effects Of Antipsychotic Drugs

Download Life Threatening Effects Of Antipsychotic Drugs Full eBooks in PDF, EPUB, and kindle. Life Threatening Effects Of Antipsychotic Drugs is one my favorite book and give us some inspiration, very enjoy to read. you could read this book anywhere anytime directly from your device.

Life Threatening Effects of Antipsychotic Drugs

Life Threatening Effects of Antipsychotic Drugs Book
Author : Peter Manu,Robert J. Flanagan,Kathlyn J. Ronaldson
Publisher : Academic Press
Release : 2016-08-16
ISBN : 0128033908
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Life-Threatening Effects of Antipsychotic Drugs describes in detail more than 20 life-threatening effects associated with antipsychotics, presents the best available data on their incidence and case fatality, and gives comprehensive advice on diagnosis, management and preventive strategies. In addition, the book discusses the benefit of antipsychotic medication in a range of therapeutic indications, and demonstrates the gain in life-expectancy associated with clozapine use in severe mental illness despite its serious, potentially life-threatening adverse effects. Covers cardiovascular, neurological, muscular, hematological, gastrointestinal, autonomic and metabolic effects Gives advice on risk factors, confounding diagnoses and measures to minimise seriousness Discusses clozapine rechallenge after each of its serious adverse reactions Makes suggestions for optimum management of somatic disease in those with severe mental illness, to improve life-expectancy Includes data on post-mortem considerations

Physical Health and Schizophrenia

Physical Health and Schizophrenia Book
Author : David J. Castle,Peter F. Buckley,Fiona P. Gaughran
Publisher : Oxford University Press
Release : 2017-09-08
ISBN : 0192539817
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

In comparison to the general population, people with schizophrenia and related disorders have poorer physical health and increased mortality. Whilst it is recognised that serious mental illnesses such as schizophrenia carry a reduced life expectancy, it is often assumed that suicide is the main cause of this disparity. In actuality, suicide accounts for no more than a third of the early mortality associated with schizophrenia: the vast majority is due to cardiovascular factors Physical Health and Schizophrenia offers a user-friendly guide to the physical health problems associated with schizophrenia and a clear overview of strategies and interventions to tackle these issues. Spanning eight chapters this resource covers the essential topics in a practical and easy-to-read format to suit the needs of busy clinicians. It also includes an appendix designed specifically for patients and carers, with practical tips on how to be actively involved in monitoring and managing physical health problems. Part of the Oxford Psychiatry Library series, Physical Health and Schizophrenia offers readers a fully up-to-date and valuable insight into this complex issue. With helpful key points at the start of each chapter and a clear layout, this is an essential resource for busy clinicians and researchers in any mental health field as well as those working in primary care.

Pharmacological Treatment of Mental Disorders in Primary Health Care

Pharmacological Treatment of Mental Disorders in Primary Health Care Book
Author : World Health Organization
Publisher : World Health Organization
Release : 2009
ISBN : 9241547693
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

This manual attempts to provide simple, adequate and evidence-based information to health care professionals in primary health care especially in low- and middle-income countries to be able to provide pharmacological treatment to persons with mental disorders. The manual contains basic principles of prescribing followed by chapters on medicines used in psychotic disorders; depressive disorders; bipolar disorders; generalized anxiety and sleep disorders; obsessive compulsive disorders and panic attacks; and alcohol and opioid dependence. The annexes provide information on evidence retrieval, assessment and synthesis and the peer view process.

Adverse Syndromes and Psychiatric Drugs

Adverse Syndromes and Psychiatric Drugs Book
Author : Peter Haddad,Peter M. Haddad,Serdar Dursun,Bill Deakin
Publisher : Oxford University Press
Release : 2004-05-27
ISBN : 0198527489
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Pharmacotherapy is an important part of the treatment of major phychiatric disorders. Although psychiatric drugs can have benefits for patients, adverse syndromes are common, causing distress for patients. This book will help psychiatrists, GPs pharmacists and nurses manage adverse syndromes associated with psychiatric drugs.

Mental Disorders in Primary Care

Mental Disorders in Primary Care Book
Author : André F. Carvalho,Roger S. McIntyre
Publisher : Oxford University Press
Release : 2017-02-09
ISBN : 0198746636
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Mental disorders are highly prevalent in the primary care setting, yet are frequently misdiagnosed and often inappropriately treated. The presence of unrecognized or misdiagnosed mental disorders is associated with increased service utilization and health care costs, and can significantly impact the patient's quality of life and risk of suicide. Written by experts from around the world, Mental Disorders in Primary Care offers readers with a comprehensive and evidence-based guide to the diagnosis and treatment of mental disorders in the primary care setting. Containing 21 chapters on a variety of psychiatric disorders, such as depressive disorders and substance use disorders, and key topics for discussion such as drug interactions, and collaborative care, Mental Disorders in Primary Care is essential reading for clinicians treating patients in a primary care setting. Fully up-to-date to reflect DSM-5's taxonomy of psychiatric disorders, this resource provides readers with a global and comprehensive guide to the diagnosis and treatment of patients with mental disorders.

Antipsychotic Long acting Injections

Antipsychotic Long acting Injections Book
Author : Peter Haddad,Tim Lambert,John Lauriello
Publisher : Oxford University Press
Release : 2016-05-10
ISBN : 0191045780
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Antipsychotic Long-acting Injections (LAIs) were introduced in the 1960s to improve treatment adherence in schizophrenia. Subsequently, first-generation antipsychotic LAIs became widely used in many countries. Since the initial publication of Antipsychotic Long-acting Injections in 2010, new trial data have been published on long-acting injection (LAI) preparations of the drugs Risperidone, Paliperidone, and Olanzapine. Furthermore, a new LAI preparation of the drug Aripiprazole has recently been approved for clinical use in the United States and is likely to be approved in Europe soon. The second edition of this successful book has been fully updated to include this new data, with reference to both observational studies and randomized controlled trials, as well as other new developments in the clinical use of antipsychotic LAIs. New chapters have been added covering the comparison between oral and injectable antipsychotics, Olanzapine LAI, Aripiprazole LAI, and the practicalities of organizing a specialized clinic for long-acting injectable antipsychotics. Existing chapters have also been thoroughly updated to take into account the most recently published research. Antipsychotic Long-acting Injections, Second edition brings together clinical and research findings on LAIs in a comprehensive volume, with chapters written by international experts.

The Maudsley Prescribing Guidelines in Psychiatry

The Maudsley Prescribing Guidelines in Psychiatry Book
Author : David M. Taylor,Thomas R. E. Barnes,Allan H. Young
Publisher : John Wiley & Sons
Release : 2018-07-16
ISBN : 1119442605
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

The revised 13th edition of the essential reference for the prescribing of drugs for patients with mental health disorders The revised and updated 13th edition of The Maudsley Prescribing Guidelines in Psychiatry provides up-to-date information, expert guidance on prescribing practice in mental health, including drug choice, treatment of adverse effects and how to augment or switch medications. The text covers a wide range of topics including pharmacological interventions for schizophrenia, bipolar disorder, depression and anxiety, and many other less common conditions. There is advice on prescribing in children and adolescents, in substance misuse and in special patient groups. This world-renowned guide has been written in concise terms by an expert team of psychiatrists and specialist pharmacists. The Guidelines help with complex prescribing problems and include information on prescribing psychotropic medications outside their licensed indications as well as potential interactions with other medications and substances such as alcohol, tobacco and caffeine. In addition, each of the book’s 165 sections features a full reference list so that evidence on which guidance is based can be readily accessed. This important text: Is the world’s leading clinical resource for evidence-based prescribing in day-to-day clinical practice and for formulating prescribing policy Includes referenced information on topics such as transferring from one medication to another, prescribing psychotropic medications during pregnancy or breastfeeding, and treating patients with comorbid physical conditions, including impaired renal or hepatic function. Presents guidance on complex clinical problems that may not be encountered routinely Written for psychiatrists, neuropharmacologists, pharmacists and clinical psychologists as well as nurses and medical trainees, The Maudsley Prescribing Guidelines in Psychiatry are the established reference source for ensuring the safe and effective use of medications for patients presenting with mental health problems.

First Episode Psychosis

First Episode Psychosis Book
Author : Katherine J. Aitchison,Robin M. Murray,Patrick J. R. Power,Eva M. Tsapakis
Publisher : CRC Press
Release : 1999-02-17
ISBN : 9781853174353
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

The new edition of this popular handbook has been thoroughly updated to include the latest data concerning treatment of first-episode patients. Drawing from their experience, the authors discuss the presentation and assessment of the first psychotic episode and review the appropriate use of antipsychotic agents and psychosocial approaches in effective management.

The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia

The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia Book
Author : American Psychiatric Association
Publisher : American Psychiatric Pub
Release : 2016
ISBN : 0890426775
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Dementia is associated with a sizeable public health burden that is growing rapidly as the population ages. In addition to cognitive impairments, individuals with dementia often come to clinical attention because of symptoms of a behavioral disturbance (e.g., irritability, agitation, aggression) or psychosis. The burden on caregivers is substantial and is increased when dementia is associated with behavioral and psychological symptoms, and particularly with agitation or aggression. Treatment of psychotic symptoms and agitation in individuals with dementia has often involved use of antipsychotic medications. In recent years, the risks associated with use of these agents in the older adult population have become apparent. There has been a growing need to develop guidelines for appropriate use of antipsychotic medications in dementia. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia seeks to fulfill this need to improve the care of patients with dementia who are exhibiting agitation or psychosis. The guideline focuses on the judicious use of antipsychotic medications when agitation or psychosis occurs in association with dementia. It is intended to apply to individuals with dementia in all settings of care as well as to care delivered by generalist and specialist clinicians. The guideline offers clear, concise, and actionable recommendation statements to help clinicians to incorporate recommendations into clinical practice, with the goal of improving quality of care. Each recommendation is given a rating that reflects the level of confidence that potential benefits of an intervention outweigh potential harms. Findings from an expert opinion survey have also been taken into consideration in making recommendations or suggestions. In addition to reviewing the available evidence on use of antipsychotics in treating agitation or psychosis in patients with dementia, the guideline provides guidance to clinicians on implementing these recommendations to enhance patient care.

Antipsychotics and their Side Effects

Antipsychotics and their Side Effects Book
Author : David M. Gardner,Michael D. Teehan
Publisher : Cambridge University Press
Release : 2010-11-11
ISBN : 113949192X
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

With the remarkable expansion in the use of antipsychotics, concerns about their immediate, intermediate, and long-term adverse effects have intensified. Despite this, studies consistently show that monitoring of patients taking antipsychotics can be inadequate, haphazard, or worse. This book provides a comprehensive review of the adverse effects of this pharmacologically complex therapeutic class, covering all commonly used conventional and atypical agents. In the first section, each chapter provides background information about an adverse effect, reviews the evidence linking the effect to various antipsychotics, and provides specific detection and monitoring recommendations. The second section provides unique monitoring guides for each antipsychotic. The third section provides the clinician with a program to monitor patients over the long-term. By supporting rational treatment decisions and systematic adverse effect monitoring, Antipsychotics and their Side Effects provides the clinician with the necessary information and tools for optimizing the safe and effective long-term use of antipsychotic drugs.

Drug Induced Movement Disorders

Drug Induced Movement Disorders Book
Author : Stewart Factor,Anthony Lang,William Weiner
Publisher : John Wiley & Sons
Release : 2008-04-15
ISBN : 140513755X
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

The second revised edition of this text will update and present current state of the art clinical approaches to this subject. This book will continue to be the source text of information on drug-induced movement disorders authored and edited by the pioneers in the field. It will be an invaluable addition to the library of any neurologist.

Treatment Refractory Schizophrenia

Treatment   Refractory Schizophrenia Book
Author : Peter F. Buckley,Fiona Gaughran
Publisher : Springer Science & Business Media
Release : 2014-03-18
ISBN : 3642452574
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Schizophrenia is often associated with an inadequate response to pharmacological and non-pharmacological treatments. How to treat patients who have an unsatisfactory response to anti-psychotics, including clozapine - which is unequivocally the most powerful antipsychotic medication for this recalcitrant population - remains a clinical conundrum. A range of adjunctive medications have been tried with mixed results; there has also been renewed interest in the role of neuromodulatory strategies, electroconvulsive therapy, and cognitive and vocational approaches. Perhaps a bright spot for the future lies in the evolution of pharmacogenetic approaches for individualized care. In this book, leading experts from Europe, Australia and the Americas provide a timely appraisal of treatments for the most severely ill schizophrenia patients. This clinically focused book is informed by the latest research on the neurobiology and treatment of schizophrenia. It is comprehensive in scope, covering current treatment options, various add-on approaches, and a range of psychosocial treatments. The contributors are respected experts who have combined their clinical experience with cutting-edge research to provide readers with authoritative information on fundamental aspects of clinical care for schizophrenia.

Pharmacology

Pharmacology Book
Author : Joyce LeFever Kee,Evelyn R. Hayes,Linda E. McCuistion
Publisher : Elsevier Health Sciences
Release : 2014-01-30
ISBN : 1455751480
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Previous edition has subtitle: "a nursing process approach."

Prescriber s Guide Children and Adolescents

Prescriber s Guide    Children and Adolescents Book
Author : Stephen M. Stahl
Publisher : Cambridge University Press
Release : 2018-10-18
ISBN : 1108446566
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Supplement to Stahl's essential psychopharmacology: neuroscientific basis and practical application / Stephen M. Stahl.

Hyperkinetic Movement Disorders

Hyperkinetic Movement Disorders Book
Author : Alberto Albanese,Joseph Jankovic
Publisher : John Wiley & Sons
Release : 2012-03-07
ISBN : 1444346164
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Hyperkinetic movement disorders comprise a range of diseases characterized by unwanted and uncontrollable, or poorly controllable, involuntary movements. The phenomenology of these disorders is quite variable encompassing chorea, tremor, dystonia, myoclonus, tics, other dyskinesias, jerks and shakes. Discerning the underlying condition can be very difficult given the range and variability of symptoms. But recognizing the phenomenology and understanding the pathophysiology are essential to ensure appropriate treatment. Hyperkinetic Movement Disorders provides a clinical pathway for effective diagnosis and management of these disorders. The stellar international cast of authors distils the evidence so you can apply it into your practice. The judicious use of diagnostic criteria algorithms rating scales management guidelines Provides a robust framework for clear patient management. Throughout the text, QR codes* provide smartphone access to case-study videos of hyperkinetic symptoms. Purchase includes an enhanced Wiley Desktop Edition.* This is an interactive digital version featuring: all text and images in fully searchable form integrated videos of presentations View a sample video: www.wiley.com/go/albanese highlighting and note taking facilities book marking linking to additional references Hyperkinetic Movement Disorders provides you with the essential visual and practical tools you need to effectively diagnose and treat your patients. *Full instructions for using QR codes and for downloading your digital Wiley DeskTop Edition are inside the book.

Current Antipsychotics

Current Antipsychotics Book
Author : Gerhard Gross,Mark A. Geyer
Publisher : Springer Science & Business Media
Release : 2012-11-05
ISBN : 3642257615
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical needs, i.e. poorly treated domains of schizophrenia, improved acceptance by patients, better adherence to medication, safety in psychoses in demented patients, and avoiding cardiac and metabolic adverse effects. The first completely novel mechanisms evolving from our insights into the pathophysiology of psychotic disorders, especially the role of glutamatergic mechanisms in schizophrenia, are now under development, and further principles are on the horizon. This situation, in many respects similar to that when the initial second-generation antipsychotics became available, can be rewarding for all. Preclinical and clinical researchers now have the opportunity to confirm their hypotheses and the pharmaceutical industry may be able to develop really novel classes of therapeutics. When we were approached by the publishers of the Handbook of Experimental Pharmacology to prepare a new volume on antipsychotics, our intention was to capture both, the accumulated preclinical and clinical knowledge about current antipsychotics as well as prospects for new and potentially more specific antischizophrenia principles. These efforts should be based on the pathophysiology of the diseases and the affected neurotransmitter systems. Since preclinical research on antipsychotic compounds is only reliable when intimately linked through translational aspects to clinical results, we decided to include clinical science as well. It turned out that that this endeavor could not be covered by a single volume. We thank the editorial board and the publishers for supporting our decision to prepare two volumes: Current Antipsychotics and Novel Antischizophrenia Treatments. These topics cannot really be separated from one another and should be seen as a composite entity despite the somewhat arbitrary separation of contributions into two volumes. The continuing challenges of developing improved and safer antipsychotic medications remain of concern and are discussed in the first volume. The new opportunities for the field to develop and license adjunctive treatments for the negative symptoms and cognitive deficits that are treated inadequately by existing compounds have been incentivized recently and provide the focus for the second volume. We hope these collective contributions will facilitate the development of improved treatments for the full range of symptomatology seen in the group of schizophrenias and other major psychotic disorders. Gerhard Gross, Ludwigshafen, Germany Mark A. Geyer, La Jolla, CA This volume will try to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters will also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. Non-schizophrenia indications will be covered to some extent, but not exhaustively.

Tardive Dyskinesia

Tardive Dyskinesia Book
Author : American Psychiatric Association. Task Force on Tardive Dyskinesia
Publisher : American Psychiatric Pub
Release : 1992
ISBN : 9780890422304
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Since the APA's last report on tardive dyskinesia in 1979, considerable research has been conducted on the prevalence, incidence, and risk factors associated with the development of late-occurring neuroleptic side effects. This book summarizes the progress made over the last decade in understanding the differential diagnosis and epidemiology of tardive dyskinesia, as well as risk factors, course, and treatment. The reader will benefit from the book's coverage of * indications for neuroleptic use* alternative maintenance strategies* factors to consider in making a differential diagnosis* frequently encountered problems in dealing with special populations such as children and mentally retarded people* clinical-legal issues related to tardive dyskinesia * clearly specified recommendations for prevention and management

The Recognition and Management of Early Psychosis

The Recognition and Management of Early Psychosis Book
Author : Patrick D. McGorry,Henry J. Jackson
Publisher : Cambridge University Press
Release : 1999-07-28
ISBN : 1139429140
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

The treatment of early psychosis has been bedevilled by an entrenched pessimism, stemming from the asylum era and the Kraepelinian model of schizophrenia. More recently, however, there has been a surge of interest in preventively oriented treatment of patients showing the first signs of psychotic illness, with the realization that these illnesses are frequently highly responsive to early treatment. This is the first text to focus on the potential of early detection of psychosis, and the practicalities of treatment. Based on the pioneering experience and research of a now well-established prevention and intervention centre, and with contributions from international authorities, the book outlines a framework for intervention, reviews the evidence available to guide clinical practice, and describes models of treatment. Incorporating many personal narratives and case histories, it is strong on theory, sensitive on practical issues, and will challenge, inform and guide clinicians.

Antipsychotic Trials in Schizophrenia

Antipsychotic Trials in Schizophrenia Book
Author : T. Scott Stroup,Jeffrey A. Lieberman
Publisher : Cambridge University Press
Release : 2010-04-01
ISBN : 1139487574
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Antipsychotic medications are a key treatment for schizophrenia and sales of antipsychotic drugs approach $20 billion per year, with fierce marketing between the makers of the drugs. The U.S. National Institute of Mental Health sponsored the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project to provide independent information about the comparative effectiveness of medications. CATIE was the largest, longest and most comprehensive study of schizophrenia to date. Conducted under rigorous double-blind conditions, Antipsychotic Trials in Schizophrenia presents the definitive archival results of this landmark study. The core of the book consists of chapters focused on specific outcomes that set the CATIE findings in a wider context. Also included are chapters on the design, statistical analyses and implications for researchers, clinicians and policy makers. Psychiatrists, psychiatric researchers, mental health policy makers and those working in pharmaceutical companies will all find this to be essential reading.